Emergent Biosolutions INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NYSE
Emergent BioSolutions Inc. reported a net income of $52.6 million in 2025, a significant turnaround from prior year losses, despite a 29% decrease in total revenues.
NYSE
10-K: Emergent BioSolutions Reports Fiscal Year 2024 Results, Outlines Strategic Priorities for 2025
Emergent BioSolutions details its FY2024 financial performance, strategic restructuring, and sets sights on a turnaround in 2025 with a focus on core products and international expansion.
NYSE
10-K: Emergent BioSolutions Implements Compensation Recovery Policy and Reports Full Year 2023 Results
Emergent BioSolutions has adopted a new compensation recovery policy and released its full year 2023 financial results, including a strategic shift in its business focus.